亿帆医药：断金戒毒胶囊Ib期临床试验结果达到预期目标

Core Viewpoint - Yifan Pharmaceutical's subsidiary, Suzhou Yifan Pharmaceutical Co., Ltd., has completed Phase Ib clinical trials for the drug "Duanjin Detoxification Capsule" aimed at treating opioid addiction relapse prevention in China, demonstrating good safety, tolerability, and pharmacokinetic characteristics [1] Group 1: Clinical Trial Results - The clinical trial results indicate that Duanjin Detoxification Capsule shows a significant trend in preventing relapse, improving behavioral control, and enhancing rehabilitation quality compared to a placebo in patients recovering from opioid addiction [1] - The trial results met the expected goals, suggesting a positive outlook for the drug's potential market entry [1] Group 2: Financial Impact - The recent trial results are not expected to have a significant impact on the company's short-term performance; however, approval and market launch of Duanjin Detoxification Capsule could positively influence future earnings [1]